271 related articles for article (PubMed ID: 23583496)
1. Multiplexed immunoassay to assess Shigella-specific antibody responses.
Kaminski RW; Clarkson K; Kordis AA; Oaks EV
J Immunol Methods; 2013 Jul; 393(1-2):18-29. PubMed ID: 23583496
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
3. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
[No Abstract] [Full Text] [Related]
4. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
mSphere; 2018; 3(2):. PubMed ID: 29600284
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.
Riddle MS; Kaminski RW; Williams C; Porter C; Baqar S; Kordis A; Gilliland T; Lapa J; Coughlin M; Soltis C; Jones E; Saunders J; Keiser PB; Ranallo RT; Gormley R; Nelson M; Turbyfill KR; Tribble D; Oaks EV
Vaccine; 2011 Sep; 29(40):7009-19. PubMed ID: 21787825
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody responses against shigella lipopolysaccharides and invasion plasmid-coded antigens in shigella infected Swedish patients.
Li A; Rong ZC; Ekwall E; Forsum U; Lindberg AA
Scand J Infect Dis; 1993; 25(5):569-77. PubMed ID: 8284641
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides.
Oberhelman RA; Kopecko DJ; Salazar-Lindo E; Gotuzzo E; Buysse JM; Venkatesan MM; Yi A; Fernandez-Prada C; Guzman M; León-Barúa R
Infect Immun; 1991 Jul; 59(7):2341-50. PubMed ID: 2050402
[TBL] [Abstract][Full Text] [Related]
8. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
[TBL] [Abstract][Full Text] [Related]
9. A Novel
Ndungo E; Randall A; Hazen TH; Kania DA; Trappl-Kimmons K; Liang X; Barry EM; Kotloff KL; Chakraborty S; Mani S; Rasko DA; Pasetti MF
mSphere; 2018 Aug; 3(4):. PubMed ID: 30068560
[No Abstract] [Full Text] [Related]
10. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
[TBL] [Abstract][Full Text] [Related]
11. Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.
Heine SJ; Franco-Mahecha OL; Chen X; Choudhari S; Blackwelder WC; van Roosmalen ML; Leenhouts K; Picking WL; Pasetti MF
Immunol Cell Biol; 2015 Aug; 93(7):641-52. PubMed ID: 25776843
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and biologically active production of IpaD N-terminal region.
Hesaraki M; Saadati M; Honari H; Olad G; Heiat M; Malaei F; Ranjbar R
Biologicals; 2013 Jul; 41(4):269-74. PubMed ID: 23731655
[TBL] [Abstract][Full Text] [Related]
13. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
[TBL] [Abstract][Full Text] [Related]
14. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
15. Cross-protection provided by live Shigella mutants lacking major antigens.
Szijártó V; Hunyadi-Gulyás E; Emődy L; Pál T; Nagy G
Int J Med Microbiol; 2013 May; 303(4):167-75. PubMed ID: 23567193
[TBL] [Abstract][Full Text] [Related]
16. An approach to chimeric subunit immunogen provides efficient protection against toxicity, type III and type v secretion systems of Shigella.
Felegary A; Nazarian S; Kordbacheh E; Fathi J; Minae ME
Int Immunopharmacol; 2021 Nov; 100():108132. PubMed ID: 34508943
[TBL] [Abstract][Full Text] [Related]
17. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp.
Oaks EV; Hale TL; Formal SB
Infect Immun; 1986 Jul; 53(1):57-63. PubMed ID: 3721580
[TBL] [Abstract][Full Text] [Related]
18. IpaD-loaded N-trimethyl Chitosan Nanoparticles Can Efficiently Protect Guinea Pigs against Shigella flexneri.
Akbari MR; Saadati M; Honari H; Ghorbani HM
Iran J Immunol; 2019 Sep; 16(3):212-224. PubMed ID: 31552830
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
Shim DH; Chang SY; Park SM; Jang H; Carbis R; Czerkinsky C; Uematsu S; Akira S; Kweon MN
Vaccine; 2007 Jun; 25(25):4828-36. PubMed ID: 17507120
[TBL] [Abstract][Full Text] [Related]
20. Antibody response of monkeys to invasion plasmid antigen D after infection with Shigella spp.
Oaks EV; Picking WD; Picking WL
Clin Diagn Lab Immunol; 1996 Mar; 3(2):242-5. PubMed ID: 8991646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
